Sign in to continue:

Wednesday, February 25th, 2026

Tianli International Holdings Director Luo Shi Increases Shareholding, Signals Confidence in Company Prospects




Tianli International Holdings Limited: Director Luo Shi Increases Shareholding

Tianli International Holdings Limited: Director Luo Shi Increases Shareholding

Key Highlights

  • Director Share Purchase: On 23 February 2026, Mr. Luo Shi, Chairman, Executive Director, and Chief Executive Officer of Tianli International Holdings Limited, purchased 2,700,000 ordinary shares of the Company.
  • Transaction Details: The shares were acquired via open market transactions at an average price of approximately HK\$2.79 per share.
  • Increase in Shareholding: Following the purchase, Mr. Luo holds a total of 935,534,569 shares, representing about 44.77% of the Company’s total issued shares (excluding 13,227,000 shares repurchased but not yet canceled, and 6,500,000 treasury shares held by the Company).
  • Share Options: Mr. Luo has also been granted 30,000,000 share options under the Share Option Scheme. None of these options have been exercised to date.
  • Potential Further Purchases: Mr. Luo has expressed confidence in the Group’s business outlook and does not rule out further increases in his shareholding, subject to compliance with laws and regulations.
  • Public Float Maintained: The Company continues to meet the public float requirements under the Hong Kong Stock Exchange rules, ensuring regulatory compliance after the increase in Mr. Luo’s shareholding.

Implications for Shareholders and Investors

  • Positive Signal: A substantial purchase of shares by the Company’s Chairman and CEO demonstrates strong confidence in the Group’s future prospects. This insider buying activity is often seen as a positive signal by the market and could potentially influence share price appreciation.
  • Potential Price Sensitivity: The fact that Mr. Luo now holds nearly 45% of the issued shares, together with the possibility of further purchases, may be price sensitive. Investors should monitor for any subsequent transactions or disclosures that could affect share liquidity or price.
  • Share Option Scheme: The 30,000,000 share options granted to Mr. Luo, though unexercised, represent a significant future potential dilution. Investors should consider this factor when assessing the Company’s share capital structure and any future share price impacts.
  • Public Float Compliance: The Company has assured shareholders that it remains in compliance with public float requirements, which is critical for maintaining the stock’s listing status and market stability.
  • Caution Advised: The Company recommends that shareholders and investors exercise due caution when dealing in its securities, given these developments.

Additional Details

  • Board Composition: As of the announcement date, the Board comprises nine directors, including Mr. Luo Shi and Mr. Wang Rui as executive directors, three non-executive directors, and three independent non-executive directors.
  • Transaction Date: The share purchase was conducted on 23 February 2026.

Conclusion

Mr. Luo Shi’s increased stake in Tianli International Holdings Limited, combined with his public confidence in the Company’s outlook and the possibility of further purchases, is a noteworthy development. This insider buying activity, coupled with a substantial holding, is likely to be interpreted positively by the market and may drive share price movement. Investors should stay alert to future disclosures and transactions by Mr. Luo, as they may further impact market dynamics.

Disclaimer

The information presented above is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with professional advisors before making any investment decisions. The Company has advised caution in dealing with its securities following these developments.




View TIANLI INT HLDG Historical chart here



Ruxolitinib Phosphate Cream for Atopic Dermatitis Granted Priority Review in China—China Medical System Announces NDA Acceptance and Business Update 1

China Medical System Announces Key Regulatory Milestone for Ruxolitinib Phosphate Cream in Atopic Dermatitis China Medical System’s Dermavon Achieves Major Regulatory Milestone: Ruxolitinib Phosphate Cream NDA for Atopic Dermatitis Accepted and Granted Priority Review...

APT Electronics Announces Discloseable Transaction for RMB668 Million Semiconductor Fund Formation in Guangzhou

APT Electronics Announces Discloseable Transaction: Formation of RMB668 Million Semiconductor-Focused Fund APT Electronics Co., Ltd. Announces Major Investment in New RMB668 Million Semiconductor Fund Key Highlights for Investors Significant Capital Commitment: APT Electronics will...

ZTE Corporation Board Meeting Notice to Approve 2025 Annual Results and Profit Distribution

ZTE Corporation Board Meeting Announcement – Key Details for Investors ZTE Corporation Announces Upcoming Board Meeting to Approve 2025 Annual Results ZTE Corporation (Stock Code: 00763), one of China’s leading telecommunications and information technology...

   Ad